-
IRBs should work to create balanced IRB discussions and ensure cooperation between members of diverse backgrounds.
-
-
Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
Immunochemical fecal occult blood testing (i-FOBT) is becoming increasingly popular as a screening tool for colorectal cancer (CRC).
-
Easily obtained clinical variables can identify patients at very low risk for subarachnoid hemorrhage.
-
Tiotropium for uncontrolled asthma, sibutramine pulled from market, incidence and mortality data from WHI, FDA Actions
-
The ECG shown above was obtained from an older man with palpitations. He was hemodynamically stable with a systolic BP of 140 mm Hg at the time this tracing was recorded. How do you interpret the rhythm? What are your initial priorities?
-
A decision analysis shows that active surveillance is a good option for men age 65 and older with low-risk prostate cancer (Gleason score of 6 or less). Active surveillance results in the highest quality-of-life scores compared with different treatment options, and 61% of these men will go on to treatment after a median of 8.5 years, with a slight increased mortality risk. Only 10% of men currently receive active surveillance for low-risk prostate cancer
-
The most recent advice from the U.S. Department of Agriculture (2005) recommends that the general population of adults not consume > 2300 mg/day of sodium, and that persons with hypertension (HTN) consume ≤ 1500 mg/day.
-
The first oral contraceptive combined with a folate has been approved by the FDA.